Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NORshock
2024-510892-40-00Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 4, randomised trial of norepinephrine in cardiogenic shock and myocardial infarction (MI) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Composite of all-cause mortality and severe renal failure requiring renal replacement therapy within 30 days after randomization. Planned start Feb 2024; status: authorised.
02
Drugs
norepinephrine
03
Conditions
cardiogenic shockmyocardial infarction (MI)
Beyond the preview
Go deeper on 2024-510892-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510892-40-00.